Results 151 to 160 of about 106,346 (224)

PRMT1 promotes immune escape in hepatocellular carcinoma by regulating arginine methylation modification of MYC protein. [PDF]

Epigenetics
Zhou H, Wang Y, Wang D, Zhang M, Wang K, Liu C.   +5 more
europepmc   +1 more source

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes

The Journal of Pathology, EarlyView.
Abstract Pancreatic ductal adenocarcinomas (PDACs) with wild‐type KRAS constitute a small fraction of PDACs, and these tumors were recently shown to harbor frequent actionable oncogenic mutations and fusions. However, the clinicopathological features of KRAS wild‐type PDAC have not been well studied.
Kazuhiro Toriyama, Katsuhiro Masago, Noriko Shibata, Masataka Haneda, Takamichi Kuwahara, Seiji Natsume, Shota Kobayashi, Yasuko Fujita, Eiichi Sasaki, Kenji Yamao, Hiroki Kawashima, Yasuhiro Shimizu, Kazuo Hara, Yasushi Yatabe, Waki Hosoda   +14 more
wiley   +1 more source

DNA methylation memory of pancreatic acinar-ductal metaplasia transition state altering Kras-downstream PI3K and Rho GTPase signaling in the absence of Kras mutation. [PDF]

Genome Med
Lo EKW, Idrizi A, Tryggvadottir R, Zhou W, Hou W, Ji H, Cahan P, Feinberg AP.   +7 more
europepmc   +1 more source

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

The Journal of Pathology, EarlyView.
Abstract In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Timár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics, Miklós Egyed, Zsuzsa Molnár, János Rottek, András Masszi, Péter Tamáska, Róbert Szász, Árpád Illés, Donát Alpár, Ferenc Magyari, Csaba Bödör   +19 more
wiley   +1 more source

Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research.

Dis Model Mech
Sutter L, De Cock L, Wang CC, Gorgels D, Wyns K, Verbeeck K, Vanleeuw U, Douchy T, Hompes D, Jaekers J, Van Raemdonck D, Vanden Bempt I, Debiec-Rychter M, Sciot R, Wozniak A, Schöffski P.   +15 more
europepmc   +1 more source

AEBP1 inhibition reduces cell growth and PI3K/AKT pathway while less regulates cell mobility in hepatocellular carcinoma. [PDF]

World J Surg Oncol
Liu L, Cai Q, Wu D, Li S, Liu D, Zheng J.   +5 more
europepmc   +1 more source

IL‐21 Loading CaMnCO3 Vitality Backpacks Boost CAR‐T Cell Synergistic Immunotherapy

Small, EarlyView.
This work designs CaMnCO3 nanoparticles loaded with IL‐21, which simultaneously alleviates the acidity and hypoxia of the tumor microenvironment, serving as vitality backpacks for CAR‐T cells. These nanoparticles consistently enhance the effectiveness of CAR‐T cell therapy against solid tumors in both low‐ and high‐dose infusion models by gradually and
Baihui Wang, Yuchan Xue, Yang Jia, Yuyao Duan, Dejun Li, Minghao Sui, Yuemin Feng, Le Wang, Han Ding, Xinyu Wang, Tianru Zhang, Yanning Sun, Huimin Liu, Jianni Qi, Jiazhi Duan, Songbo Zhao, Qiang Zhu   +16 more
wiley   +1 more source

First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma. [PDF]

Curr Oncol
De Pas TM, Giaccone G, Catania C, Conforti F, Pala L, Mitsakis P, Dietrich PY.   +6 more
europepmc   +1 more source

Clustering of Membrane Receptors: Insights from DNA Origami‐Based Approaches

Small, EarlyView.
Receptor clustering critically influences cell signaling, yet its precise regulation remains elusive. This review highlights how DNA origami structures serve as nanoscale tools to uncover receptor organization and provide new insights into signal transduction.
Carmen M. Domínguez, Christof M. Niemeyer   +1 more
wiley   +1 more source

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. [PDF]

Front Immunol
De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C, Bravaccini S, Delmonte A, Crinò L, Borges de Souza P, Pasini L, Nicolini F, Bianchi F, Juan M, Calderon H, Magnoni C, Gazzola L, Ulivi P, Mazza M.   +18 more
europepmc   +1 more source